Johnson & Johnson Stock Drops 4.05% in Three Days as Trading Volume Ranks 88th

On June 18, 2025, Johnson & Johnson (JNJ) experienced a decline of 1.08%, marking its third consecutive day of losses, with a total decrease of 4.05% over the past three days. The trading volume for the day was 8.02 billion, placing it at the 88th position in the daily market rankings.

Johnson & Johnson has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration (FDA) to expand the use of STELARA (ustekinumab) for treating children aged two years and older with Crohn's disease. This application is supported by 52-week data from a Phase 3 study, which demonstrated the drug's efficacy and safety in pediatric patients. Currently, STELARA is approved for treating adults with moderately to severely active Crohn's disease and ulcerative colitis, as well as for other indications.

This move by Johnson & Johnson to seek FDA approval for STELARA in pediatric Crohn's disease is a strategic effort to expand the drug's market and address an unmet medical need. If approved, STELARA could become a significant treatment option for younger patients suffering from this chronic inflammatory bowel disease. The potential expansion of STELARA's indications could positively impact Johnson & Johnson's revenue and market position in the biopharmaceutical sector.